Biogen Inc
Biogen Inc (BIIB) Wheel Strategy
BIIB wheel strategy scan found 179 cash-secured put setups on the previous trading day. Probability of expiring worthless is above 50%. Annualized returns reach up to 88.8%.
Read more
Running a BIIB wheel strategy lets you generate consistent premium income on Biogen Inc while setting your own entry and exit prices on the underlying. Biogen Inc's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own BIIB, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best BIIB wheel strategy setups in real time.
The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on BIIB, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable BIIB wheel from a losing one.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies.
Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the BIIB wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your BIIB wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.
| Oct 2, 2026 | 227.50 | $2.15 | $3.88 | -0.48 | 7 | 28% | 50.2% | 88.8% | 1 |
| Oct 2, 2026 | 225.00 | $0.70 | $2.70 | -0.38 | 7 | 28% | 60.0% | 62.6% | 1 |
| Oct 9, 2026 | 225.00 | $1.70 | $3.70 | -0.40 | 14 | 28% | 56.9% | 42.9% | 0 |
| Oct 30, 2026 | 225.00 | $6.70 | $8.85 | -0.42 | 35 | 28% | 54.0% | 41.0% | 0 |
| Oct 16, 2026 | 225.00 | $4.40 | $5.30 | -0.41 | 21 | 28% | 55.5% | 40.9% | 1 |
| Oct 2, 2026 | 222.50 | $1.05 | $1.60 | -0.28 | 7 | 28% | 69.3% | 37.5% | 1 |
| Nov 6, 2026 | 225.00 | $7.70 | $9.60 | -0.42 | 42 | 28% | 53.6% | 37.1% | 0 |
| Oct 23, 2026 | 225.00 | $4.60 | $6.35 | -0.42 | 28 | 28% | 54.6% | 36.8% | 1 |
| Oct 9, 2026 | 222.50 | $0.90 | $2.90 | -0.33 | 14 | 28% | 63.6% | 34.0% | 0 |
| Oct 30, 2026 | 220.00 | $5.20 | $7.10 | -0.35 | 35 | 28% | 62.7% | 33.7% | 4 |
As of September 28, 2026
Run the Wheel on BIIB With Confidence
Find the best BIIB wheel strategy setups across strikes and expirations, plan ahead with at-strike values, and keep your covered calls and puts on track.
Start your 14-day free trial→